Evidence for Long-term Efficacy and Safety of Gene Therapy for Wiskott–Aldrich Syndrome in Preclinical Models

This publication has 52 references indexed in Scilit:

• WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function
  Blood, 2008
• Recent advances in gene therapy for severe congenital immunodeficiency diseases
  Current Opinion in Hematology, 2008
• Unrelated Bone Marrow Transplantation with a Reduced Toxicity Myeloablative Conditioning Regimen in Wiskott-Aldrich Syndrome
  Journal of Korean Medical Science, 2008
• Unregulated actin polymerization by WASp causes defects of mitosis and cytokinesis in X-linked neutropenia
  The Journal of Experimental Medicine, 2007
• Importance of Murine Study Design for Testing Toxicity of Retroviral Vectors in Support of Phase I Trials
  Molecular Therapy, 2007
• WIP is a chaperone for Wiskott–Aldrich syndrome protein (WASP)
  Proceedings of the National Academy of Sciences, 2007
• Stem cell transplantation for the Wiskott–Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation
  Bone Marrow Transplantation, 2006
• Therapeutic gene causing lymphoma
  Nature, 2006
• Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect
  Blood, 2004
• Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice
  Blood, 2002